Osteoporosis International

, Volume 20, Issue 2, pp 283–290

Effectiveness of antiresorptives for the prevention of nonvertebral low-trauma fractures in a population-based cohort of women

  • L. A. Langsetmo
  • S. Morin
  • J. B. Richards
  • K. S. Davison
  • W. P. Olszynski
  • J. C. Prior
  • R. Josse
  • D. Goltzman
  • *CaMos Research Group
Original Article



Observational studies are needed to quantify real-life effectiveness of antiresorptive therapy in the prevention of clinical fractures. Antiresorptive therapies were associated with an overall 32% reduction in low-trauma nonvertebral fracture risk among women 50 and older. Effectiveness may be lower among older women and those without risk factors.


Randomized controlled trials have shown that antiresorptive therapies reduce the risk of fracture in selected populations, but further study is needed to quantify their real-life effectiveness. The study objective was to determine the association between antiresorptive use and low-trauma nonvertebral fracture in women 50 and older.


The design was a retrospective nested case-control study (density-based sampling) within the Canadian Multicentre Osteoporosis Study. There were 5,979 eligible women with 453 cases and 1,304 matched controls.


The current use of antiresorptives was associated with a decreased risk of fracture with OR = 0.68, 95% CI: 0.52–0.91; where OR is the adjusted odds ratio and CI is the confidence interval. Subgroup analysis yielded OR = 0.61, 95% CI: 0.42–0.89 for ages 50–74; OR = 0.76, 95% CI: 0.50–1.17 for ages 75+; OR = 0.58, 95% CI: 0.40–0.83 for those with a major risk factor; and OR = 0.92; 95% CI: 0.59–1.42 for those without a major risk factor. Major risk factors were prevalent low-trauma fracture, vertebral deformity (grade 2+), and BMD T-score ≤ −2.5.


Antiresorptive therapy is associated with a clinically important reduction in low-trauma nonvertebral fracture risk among community-dwelling women aged 50 and older. Antiresorptive therapy may be less effective for women 75 and older and women without major risk factors.


Antiresorptive Bisphosphonates Fractures Hormone replacement therapy Nested case-control study Osteoporosis 


  1. 1.
    Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367(9527):2010–2018PubMedCrossRefGoogle Scholar
  2. 2.
    Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733PubMedCrossRefGoogle Scholar
  3. 3.
    Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E (2001) Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 12(4):271–278PubMedCrossRefGoogle Scholar
  4. 4.
    Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23(4):570–578PubMedCrossRefGoogle Scholar
  5. 5.
    Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRefGoogle Scholar
  6. 6.
    Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352PubMedCrossRefGoogle Scholar
  7. 7.
    Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124PubMedCrossRefGoogle Scholar
  8. 8.
    Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 10(2):142–151PubMedGoogle Scholar
  9. 9.
    Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18(1):25–34PubMedCrossRefGoogle Scholar
  10. 10.
    Van Staa TP, Abenhaim L, Cooper C (1998) Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 37(1):87–94PubMedCrossRefGoogle Scholar
  11. 11.
    Kreiger N, Tenenhouse A, Joseph L et al (1999) Research notes: the Canadian Multicentre Osteoporosis Study (CaMos)—background, rationale, methods. Can J Aging 18:376–387Google Scholar
  12. 12.
    Rothman K (2002) Epidemiology: an Introduction. Oxford University Press, New YorkGoogle Scholar
  13. 13.
    Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427PubMedCrossRefGoogle Scholar
  14. 14.
    Jackson SA, Tenenhouse A, Robertson L (2000) Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 11(8):680–687PubMedCrossRefGoogle Scholar
  15. 15.
    Shah BR, Laupacis A, Hux JE, Austin PC (2005) Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 58(6):550–559PubMedCrossRefGoogle Scholar
  16. 16.
    Boonen S, McClung MR, Eastell R, El-Hajj FG, Barton IP, Delmas P (2004) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52(11):1832–1839PubMedCrossRefGoogle Scholar
  17. 17.
    Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280(24):2077–2082PubMedCrossRefGoogle Scholar
  18. 18.
    Whiting SJ, Green TJ, Calvo MS (2007) Vitamin D intakes in North America and Asia-Pacific countries are not sufficient to prevent vitamin D insufficiency. J Steroid Biochem Mol Biol 103(3–5):626–630PubMedCrossRefGoogle Scholar
  19. 19.
    Rucker D, Allan JA, Fick GH, Hanley DA (2002) Vitamin D insufficiency in a population of healthy western Canadians. CMAJ 166(12):1517–1524PubMedGoogle Scholar
  20. 20.
    Heckman GA, Papaioannou A, Sebaldt RJ et al (2002) Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 3:6PubMedCrossRefGoogle Scholar
  21. 21.
    Brown JP, Josse RG (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 [10 Suppl]:S1–S34PubMedGoogle Scholar
  22. 22.
    Majumdar SR, McAlister FA, Furberg CD (2004) From knowledge to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol 43(10):1738–1742PubMedCrossRefGoogle Scholar
  23. 23.
    Papaioannou A, Giangregorio L, Kvern B, Boulos P, Ioannidis G, Adachi JD (2004) The osteoporosis care gap in Canada. BMC Musculoskelet Disord 5:11PubMedCrossRefGoogle Scholar
  24. 24.
    Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35(5):293–305PubMedCrossRefGoogle Scholar
  25. 25.
    D’Agostino RB Jr, D’Agostino RB Sr (2007) Estimating treatment effects using observational data. JAMA 297(3):314–316PubMedCrossRefGoogle Scholar
  26. 26.
    Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342(25):1878–1886PubMedCrossRefGoogle Scholar
  27. 27.
    Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927–2938PubMedCrossRefGoogle Scholar
  28. 28.
    Greenspan SL, Emkey RD, Bone HG et al (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137(11):875–883PubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2008

Authors and Affiliations

  • L. A. Langsetmo
    • 1
  • S. Morin
    • 2
  • J. B. Richards
    • 2
  • K. S. Davison
    • 3
  • W. P. Olszynski
    • 4
  • J. C. Prior
    • 5
  • R. Josse
    • 6
  • D. Goltzman
    • 2
    • 7
  • *CaMos Research Group
  1. 1.CaMos National Coordinating CentreMontrealCanada
  2. 2.McGill UniversityMontrealCanada
  3. 3.University of LavalQuebecCanada
  4. 4.University of SaskatchewanSaskatoonCanada
  5. 5.University of British ColumbiaVancouverCanada
  6. 6.University of TorontoTorontoCanada
  7. 7.CaMos, Royal Victoria HospitalMontréalCanada
  8. 8.King’s CollegeLondonUK

Personalised recommendations